BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
“Silence’s area of biotech is moving incredibly quickly. The company could play a big role and I’m delighted to be joining at this time,” he said.
BHS auditor PwC questioned over why it described the embattled retailer as a 'going concern' days before it was sold for £1
KPMG raised concerns over Retail Acquisition's ability to continue to trade and fund both BHS
Grant Thornton adds another partner to its ranks, appointing a 20-year veteran to its Actuarial and Risk team
Queen's Speech legislation aims to crackdown on financial crime and protect those who have money in some auto enrolment schemes